CMS Reverses Course on Changing HCPCS Codes, Billing Units for Ig
NHIA commends CMS for listening to stakeholders and deciding not to move forward at this time with the proposed changes to HCPCS codes and billing units for immune globulin products.
September 19, 2023
On Tuesday, September 19, 2023, the House Energy & Commerce Health Subcommittee held a legislative hearing, “Examining Policies to Improve Seniors’ Access to Innovative Drugs, Medical Devices, and Technology.” Home infusion was discussed at least 3 distinct times throughout the hearing, with a consensus that Medicare needs to improve beneficiary access to home infusion services.
Rep. Debbie Dingell (D-MI) brought to light two bills—the Expanding Care in the Home Act and the Preserving Patient Access to Home Infusion Act—aimed at modernizing Medicare reimbursement and increasing access to home infusion services for Medicare beneficiaries. Dingell shared a personal story of a time she required several weeks of IV antibiotics through a PICC line and was able to self-administer but was shocked that this more cost-effective and sensible method was not covered by Medicare. She also reiterated that, unlike Medicare, commercial health plans almost universally cover home infusion services.
NHIA supports the comprehensive solution to home infusion coverage laid out in the Expanding Care in the Home Act and is appreciative of Rep. Dingell’s efforts and awareness around the issue.
Rep. Larry Buchon (R-IN) later aligned himself with Rep. Dingell’s comments on home infusion therapy stating that “Medicare’s policy on this has been wrong for decades.” As a cardiovascular surgeon, he said he could keep people in the hospital for 10 days and give them antibiotics but couldn’t get the IV therapy paid for if the patient went home.
Finally, Rep. Neal Dunn (R-FL) commented on new legislation that would expand the number of drugs and biologics covered under the DMEPOS home infusion benefit which requires the use of a pump. NHIA has previously expressed serious concerns to Centers for Medicare and Medicaid Services (CMS) regarding this piecemeal expansion of the DMEPOS home infusion benefit and questions the logic of adding drugs to a benefit where the service component is failing to attract providers.
“Though NHIA appreciates the multi-faceted focus on Medicare home infusion legislation, the common sense approaches outlined in Rep. Dingell’s message have the potential to provide seniors the broadest access to home infusion services while reducing costs and modernizing Medicare,” says John Rademacher, NHIA Board Chair and CEO of Option Care Health.
“The Expanding Care in the Home Act clearly outlines how to close the gaps in the current Medicare benefit for patients who prefer to access infusion services in their homes. NHIA appreciates and shares Rep. Dingell’s passion for common sense, cost-effective ways to modernize Medicare, such as adding coverage for home infusion,” says Connie Sullivan, NHIA President and CEO.
While the Expanding Care in the Home Act illustrates a well-defined vision of what a workable home infusion benefit could and should look like, Congress can take immediate steps to permanently fix the existing Part B home infusion benefit by passing the Preserving Patient Access to Home Infusion Act. Re-introduced in the 118th Congress (H.R. 4014), the Preserving Patient Access to Home Infusion Act would require CMS to pay home infusion providers for professional services each day the drug is administered and remove the requirement that a skilled professional be present in the home for billing to occur.
NHIA commends CMS for listening to stakeholders and deciding not to move forward at this time with the proposed changes to HCPCS codes and billing units for immune globulin products.
This proposal to modify the criteria for the use of an infusion pump should not be viewed as a solution to the broader access challenges facing Medicare beneficiaries who could safely receive infusion therapy at home.
NHIA submitted comments to CMS on a new proposed rule on interoperability and prior authorization for drugs. While NHIA is mostly supportive of standardizing prior authorization (PA) processes for Medicare-covered drugs, it wants CMS to know that home infusion may not fit neatly into processes designed for medical and pharmacy benefits.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |